184 related articles for article (PubMed ID: 35187628)
1. The Cost-Effectiveness of Subcutaneous Semaglutide Versus Empagliflozin in Type 2 Diabetes Uncontrolled on Metformin Alone in Denmark.
Ehlers LH; Lamotte M; Ramos MC; Sandgaard S; Holmgaard P; Kristensen MM; Ejskjaer N
Diabetes Ther; 2022 Mar; 13(3):489-503. PubMed ID: 35187628
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK.
Ramos M; Cummings MH; Ustyugova A; Raza SI; de Silva SU; Lamotte M
Diabetes Ther; 2020 Sep; 11(9):2041-2055. PubMed ID: 32700188
[TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of oral semaglutide versus empagliflozin in Type 2 diabetes in Denmark.
Ehlers LH; Lamotte M; Ramos MC; Sandgaard S; Holmgaard P; Frary EC; Ejskjaer N
J Comp Eff Res; 2022 Jan; 11(1):29-37. PubMed ID: 34841893
[No Abstract] [Full Text] [Related]
4. Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin.
Gorgojo-Martínez JJ; Malkin SJP; Martín V; Hallén N; Hunt B
J Med Econ; 2020 Feb; 23(2):193-203. PubMed ID: 31613199
[No Abstract] [Full Text] [Related]
5. The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal.
Malkin SJP; Carvalho D; Costa C; Conde V; Hunt B
Diabetol Metab Syndr; 2022 Feb; 14(1):32. PubMed ID: 35164855
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting.
Eliasson B; Ericsson Å; Fridhammar A; Nilsson A; Persson S; Chubb B
Pharmacoecon Open; 2022 May; 6(3):343-354. PubMed ID: 35064550
[TBL] [Abstract][Full Text] [Related]
7. Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme.
Bain SC; Hansen BB; Malkin SJP; Nuhoho S; Valentine WJ; Chubb B; Hunt B; Capehorn M
Diabetes Ther; 2020 Jan; 11(1):259-277. PubMed ID: 31833042
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes.
Guzauskas GF; Rind DM; Fazioli K; Chapman RH; Pearson SD; Hansen RN
J Manag Care Spec Pharm; 2021 Apr; 27(4):455-468. PubMed ID: 33769850
[No Abstract] [Full Text] [Related]
9. Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting.
Capehorn M; Hallén N; Baker-Knight J; Glah D; Hunt B
Diabetes Ther; 2021 Feb; 12(2):537-555. PubMed ID: 33423240
[TBL] [Abstract][Full Text] [Related]
10. The Cost-Effectiveness of Oral Semaglutide in Spain: A Long-Term Health Economic Analysis Based on the PIONEER Clinical Trials.
Franch-Nadal J; Malkin SJP; Hunt B; Martín V; Gallego Estébanez M; Vidal J
Adv Ther; 2022 Jul; 39(7):3180-3198. PubMed ID: 35553372
[TBL] [Abstract][Full Text] [Related]
11. The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease.
Ehlers LH; Lamotte M; Monteiro S; Sandgaard S; Holmgaard P; Frary EC; Ejskjaer N
Diabetes Ther; 2021 May; 12(5):1523-1534. PubMed ID: 33856655
[TBL] [Abstract][Full Text] [Related]
12. Early use of oral semaglutide in the UK: A cost-effectiveness analysis versus continuing metformin and SGLT-2 inhibitor therapy.
Ren H; Berry S; Malkin SJP; Hunt B; Bain S
BMJ Open; 2023 Sep; 13(9):e070473. PubMed ID: 37775297
[TBL] [Abstract][Full Text] [Related]
13. Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting.
Gæde P; Johansen P; Tikkanen CK; Pollock RF; Hunt B; Malkin SJP
Diabetes Ther; 2019 Aug; 10(4):1297-1317. PubMed ID: 31098942
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like peptide-1 receptor agonists added to insulin in patients with type 2 diabetes in China.
Feng Z; Tong WK; Zhang X; Tang Z
Front Pharmacol; 2023; 14():1226778. PubMed ID: 37621313
[No Abstract] [Full Text] [Related]
15. Cost-Effectiveness of Semaglutide vs. Empagliflozin, Canagliflozin, and Sitagliptin for Treatment of Patients with Type 2 Diabetes in Denmark: A Decision-Analytic Modelling Study.
Pulleyblank R; Larsen NB
Pharmacoecon Open; 2023 Jul; 7(4):579-591. PubMed ID: 37178435
[TBL] [Abstract][Full Text] [Related]
16. Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia.
Malkin SJP; Russel-Szymczyk M; Liidemann G; Volke V; Hunt B
Diabetes Ther; 2019 Feb; 10(1):159-176. PubMed ID: 30535837
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of the tubeless automated insulin delivery system vs standard of care in the management of type 1 diabetes in the United States.
Biskupiak JE; Ramos M; Levy CJ; Forlenza G; Hopley C; Boyd J; Swift D; Lamotte M; Brixner DI
J Manag Care Spec Pharm; 2023 Jul; 29(7):807-817. PubMed ID: 37133431
[No Abstract] [Full Text] [Related]
18. Short-term cost-effectiveness of oral semaglutide for the treatment of type 2 diabetes mellitus in the United States.
Cui J; Klepser DG; McAdam-Marx C
J Manag Care Spec Pharm; 2021 Jul; 27(7):840-845. PubMed ID: 34185562
[No Abstract] [Full Text] [Related]
19. Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease.
Ramos M; Foos V; Ustyugova A; Hau N; Gandhi P; Lamotte M
Diabetes Ther; 2019 Dec; 10(6):2153-2167. PubMed ID: 31602601
[TBL] [Abstract][Full Text] [Related]
20. Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands.
Hunt B; Malkin SJP; Moes RGJ; Huisman EL; Vandebrouck T; Wolffenbuttel BHR
BMJ Open Diabetes Res Care; 2019; 7(1):e000705. PubMed ID: 31641522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
